Temozolomide-d3

Temozolomide-d3 is the deuterium labeled Temozolomide. Temozolomide (NSC 362856) is an oral active DNA alkylating agent that crosses the blood-brain barrier. Temozolomide is also a proautophagic and proapoptotic agent. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system. Temozolomide has antitumor and antiangiogenic effects[1][2].

Product Specifications

CAS Number

[208107-14-6]

UNSPSC

12352005

Hazard Statement

H302, H340, H350, H360, H412

Target

Apoptosis; Autophagy; DNA Alkylator/Crosslinker

Type

Isotope-Labeled Compounds

Related Pathways

Apoptosis; Autophagy; Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Purity

99.87

Solubility

10 mM in DMSO|DMF : ≥ 5mg/mL|DMSO : ≥ 5mg/mL

Smiles

O=C(N1C=N2)N(N=NC1=C2C(N)=O)C([2H])([2H])[2H]

Molecular Formula

C6H3D3N6O2

Molecular Weight

197.17

Precautions

H302, H340, H350, H360, H412

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Tentori L, et al. Combined treatment with temozolomide and poly (ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood. 2002 Mar 15;99 (6) :2241-4.|[3]Perazzoli G, et al. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression. PLoS One. 2015 Oct 8;10 (10) :e0140131.|[4]Mathieu V, et al. Combining Anti-Human VEGF with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia. 2008 Dec;10 (12) :1383-92.